Clinical outcomes of dose modification during pirfenidone treatment for IPF: A nationwide post-marketing surveillance study
暂无分享,去创建一个
Jong Sun Park | S. Uh | I. Oh | J. Song | Jieun Kang | M. Park | Yun-Seong Kim | Y. Jegal | Young Whan Kim | Man Pyo Chung | Heung Bum Lee
[1] Jae Ho Lee,et al. Efficacy of lower dose pirfenidone for idiopathic pulmonary fibrosis in real practice: a retrospective cohort study , 2020, The Korean journal of internal medicine.
[2] Su Hwan Lee,et al. Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: real world experience from a tertiary university hospital , 2020, Scientific reports.
[3] Jong Sun Park,et al. Safety and Efficacy of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis: A Nationwide Post-Marketing Surveillance Study in Korean Patients , 2020, Advances in Therapy.
[4] M. Strek,et al. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat , 2019, Respiratory Research.
[5] Takeshi Johkoh,et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline , 2018, American journal of respiratory and critical care medicine.
[6] S. Nathan,et al. Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials , 2018, BMJ Open Respiratory Research.
[7] J. Stauffer,et al. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis , 2017, European Respiratory Review.
[8] D. Lynch,et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. , 2016, American journal of respiratory and critical care medicine.
[9] E. Bendstrup,et al. Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results , 2016, European clinical respiratory journal.
[10] R. D. du Bois,et al. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials , 2016, BMJ Open Respiratory Research.
[11] S. Kudoh,et al. All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis. , 2015, Respiratory investigation.
[12] Shih-Yin Chen,et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. , 2014, The Lancet. Respiratory medicine.
[13] R. Sussman,et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. , 2014, The New England journal of medicine.
[14] H. Collard,et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. , 2014, The New England journal of medicine.
[15] S. Sahn,et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis , 2014, Respirology.
[16] M. Kreuter,et al. Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events , 2014, Advances in Therapy.
[17] Joyce S Lee,et al. A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis , 2012, Annals of Internal Medicine.
[18] R. D. du Bois,et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. , 2011, Chest.
[19] S. Sahn,et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials , 2011, The Lancet.
[20] Takeshi Johkoh,et al. American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management , 2011 .
[21] H. Collard,et al. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. , 2011, American journal of respiratory and critical care medicine.
[22] G. Raghu,et al. Pirfenidone in idiopathic pulmonary fibrosis , 2009, European Respiratory Journal.
[23] J. Hankinson,et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung , 2005, European Respiratory Journal.
[24] J. Hankinson,et al. Standardisation of spirometry , 2005, European Respiratory Journal.
[25] Z. Daniil,et al. The Medical Research Council dyspnea scale in the estimation of disease severity in idiopathic pulmonary fibrosis. , 2005, Respiratory medicine.
[26] S. Kudoh,et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. , 2005, American journal of respiratory and critical care medicine.
[27] P. Jones,et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease , 1999, Thorax.